These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7430624)

  • 1. Mechanism of lethal effect of human serum upon Leishmania donovani.
    Pearson RD; Steigbigel RT
    J Immunol; 1980 Nov; 125(5):2195-201. PubMed ID: 7430624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
    Hoover DL; Berger M; Hammer CH; Meltzer MS
    J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Killing of Leishmania tropica amastigotes by factors in normal human serum.
    Hoover DL; Berger M; Nacy CA; Hockmeyer WT; Meltzer MS
    J Immunol; 1984 Feb; 132(2):893-7. PubMed ID: 6690622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth cycle-dependent generation of complement-resistant Leishmania promastigotes.
    Franke ED; McGreevy PB; Katz SP; Sacks DL
    J Immunol; 1985 Apr; 134(4):2713-8. PubMed ID: 3973390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes.
    Pearson RD; Steigbigel RT
    J Immunol; 1981 Oct; 127(4):1438-43. PubMed ID: 7276565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
    Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
    J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum.
    Hill DR; Burge JJ; Pearson RD
    J Immunol; 1984 Apr; 132(4):2046-52. PubMed ID: 6699407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania species: mechanisms of complement activation by five strains of promastigotes.
    Mosser DM; Burke SK; Coutavas EE; Wedgwood JF; Edelson PJ
    Exp Parasitol; 1986 Dec; 62(3):394-404. PubMed ID: 3780933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.
    Leddy JP; Simons RL; Douglas RG
    J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential survival of Leishmania donovani amastigotes in human monocytes.
    Pearson RD; Harcus JL; Roberts D; Donowitz GR
    J Immunol; 1983 Oct; 131(4):1994-9. PubMed ID: 6619546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum.
    Puentes SM; Dwyer DM; Bates PA; Joiner KA
    J Immunol; 1989 Dec; 143(11):3743-9. PubMed ID: 2584716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
    Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
    J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of complement-independent and antibody-mediated killing of Leishmania donovani promastigotes.
    Das A; Mazumder S; Duttagupta S
    Indian J Biochem Biophys; 1989 Aug; 26(4):249-53. PubMed ID: 2628259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of human serum for Leishmania donovani amastigotes: antibody facilitation of alternate complement pathway-mediated killing.
    Hoover DL; Berger M; Oppenheim MH; Hockmeyer WT; Meltzer MS
    Infect Immun; 1985 Jan; 47(1):247-52. PubMed ID: 3917426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania amastigotes: resistance to complement-mediated lysis is not due to a failure to fix C3.
    Mosser DM; Wedgwood JF; Edelson PJ
    J Immunol; 1985 Jun; 134(6):4128-31. PubMed ID: 3886796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies directed against O-acetylated sialoglycoconjugates accelerate complement activation in Leishmania donovani promastigotes.
    Bandyopadhyay S; Chatterjee M; Das T; Bandyopadhyay S; Sundar S; Mandal C
    J Infect Dis; 2004 Dec; 190(11):2010-9. PubMed ID: 15529267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.